PEA-15 (D110) polyclonal Antibody | BS1573

PEA-15 (D110) polyclonal Antibody | BS1573 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB

Application Range: WB: 1:500~1:1000

Background: PEA-15 (phosphoprotein enriched in astrocytes) exists in an non-phosphorylated form (N), and two phosphorylated forms, Pa and Pb. PEA-15 is an endogenous substrate for PKC, which mediates the transition from Pa to Pb. The level of PEA-15 phosphorylation changes upon depolymerization or stabilization of tubulins, indicating that PEA-15 co-localizes with microtubules. The first 80 amino acids of PEA-15 correspond to the death effector domain (DED), which is a domain found in proteins that regulate apoptotic signaling pathways. The DED domain is necessary for PEA-15 to block Ras suppression. Although PEA-15 is predominantly expressed in the central nervous system, low levels of PEA-15 are expressed in liver and kidney, and higher levels in muscle.PEA-15 is also referred to as PED, phosphoprotein enriched in diabetes, for its elevated expression in type 2 diabetic patients

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: PEA-15 (D110) polyclonal Antibody detects endogenous levels of PEA-15 protein.

Molecular Weight: ~ 15 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Astrocytic phosphoprotein PEA-15; 15 kDa phosphoprotein enriched in astrocytes; Phosphoprotein enriched in diabetes; PED; PEA15

Immunogen: Synthetic peptide, corresponding to amino acids 78-132 of Human PEA-15.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: G Protein-coupled Receptors Signaling to MAPK Erk,Cell Cycle G2 M DNA Damage Signaling Pathway,